Page 110 - 《中国药房》2023年5期

[ 2 ] PAPP V，MAGYARI M，AKTAS O，et al. Worldwide inci‐ Comparison of the efficacy of azathioprine and rituximab
dence and prevalence of neuromyelitis optica：a syste- in neuromyelitis optica spectrum disorder：a randomized
matic review[J]. Neurology，2021，96（2）：59-77. clinical trial[J]. J Neurol，2017，264（9）：2003-2009.
[ 3 ] SELLNER J，BOGGILD M，CLANET M，et al. EFNS [16] TAHARA M，OEDA T，OKADA K，et al. Safety and effi‐
guidelines on diagnosis and management of neuromyelitis cacy of rituximab in neuromyelitis optica spectrum disor‐
optica[J]. Eur J Neurol，2010，17（8）：1019-1032. ders （RIN-1 study）：a multicentre，randomised，double-
[ 4 ] 中国免疫学会神经免疫分会. 中国视神经脊髓炎谱系疾 blind，placebo-controlled trial[J]. Lancet Neurol，2020，19
病诊断与治疗指南：2021版[J]. 中国神经免疫学和神经 （4）：298-306.
病学杂志，2021，28（6）：423-436. [17] ZHANG C，ZHANG M N，QIU W，et al. Safety and effi‐
[ 5 ] LUNN D，SPIEGELHALTER D，THOMAS A，et al. The cacy of tocilizumab versus azathioprine in highly relap-
BUGS project：evolution，critique and future directions[J]. sing neuromyelitis optica spectrum disorder （TANGO）：
Stat Med，2009，28（25）：3049-3067. an open-label，multicentre，randomised，phase 2 trial[J].
[ 6 ] JANSEN J P，TRIKALINOS T，CAPPELLERI J C，et al. Lancet Neurol，2020，19（5）：391-401.
Indirect treatment comparison/network meta-analysis [18] YAMAMURA T，KLEITER I，FUJIHARA K，et al. Trial
study questionnaire to assess relevance and credibility to of satralizumab in neuromyelitis optica spectrum disorder
inform health care decision making：an ISPOR-AMCP- [J]. N Engl J Med，2019，381（22）：2114-2124.
NPC good practice task force report[J]. Value Health， [19] TRABOULSEE A，GREENBERG B M，BENNETT J L，
2014，17（2）：157-173. et al. Safety and efficacy of satralizumab monotherapy in
[ 7 ] WINGERCHUK D M，LENNON V A，LUCCHINETTI C neuromyelitis optica spectrum disorder：a randomised，
F，et al. The spectrum of neuromyelitis optica[J]. Lancet double-blind，multicentre，placebo-controlled phase 3 trial
Neurol，2007，6（9）：805-815. [J]. Lancet Neurol，2020，19（5）：402-412.
[ 8 ] WINGERCHUK D M，LENNON V A，PITTOCK S J，et [20] PITTOCK S J，BERTHELE A，FUJIHARA K，et al. Eculi‐
al. Revised diagnostic criteria for neuromyelitis optica[J]. zumab in aquaporin-4-positive neuromyelitis optica spec‐
Neurology，2006，66（10）：1485-1489. trum disorder[J]. N Engl J Med，2019，381（7）：614-625.
[ 9 ] LU G，BEADNALL H N，BARTON J，et al. The evolu‐ [21] CREE B A C，BENNETT J L，KIM H J，et al. Inebili‐
tion of “No Evidence of Disease Activity” in multiple zumab for the treatment of neuromyelitis optica spectrum
sclerosis[J]. Mult Scler Relat Disord，2018，20：231-238. disorder （N-MOmentum）：a double-blind，randomised
[10] GREEN S，HIGGINS J P. Preparing a cochrane review placebo-controlled phase 2/3 trial[J]. Lancet，2019，394
[M]//Cochrane Handbook for Systematic Reviews of Inter‐ （10206）：1352-1363.
ventions. Chichester，UK：John Wiley & Sons，Ltd.，2008： [22] MARIGNIER R，BENNETT J L，KIM H J，et al. Disabi-
11-30. lity outcomes in the N-MOmentum trial of inebilizumab
[11] MACHIN D，CHEUNG Y B，PARMAR M K B，et al. Sur‐ in neuromyelitis optica spectrum disorder[J]. Neurol Neu‐
vival analysis ：a practical approach[M]. 2nd ed. Chichester， roimmunol Neuroinflamm，2021，8（3）：e978.
Hoboken，NJ：Wiley，2006：1-25. [23] DIAS S，WELTON N J，SUTTON A J，et al. Evidence syn‐
[12] DIAS S，SUTTON A J，ADES A E，et al. Evidence synthe‐ thesis for decision making 4：inconsistency in networks of
sis for decision making 2：a generalized linear modeling evidence based on randomized controlled trials[J]. Med
framework for pairwise and network meta-analysis of ran‐ Decis Making，2013，33（5）：641-656.
domized controlled trials[J]. Med Decis Making，2013，33 [24] VAN VALKENHOEF G，DIAS S，ADES A E，et al. Auto‐
（5）：607-617. mated generation of node-splitting models for assessment
[13] WOODS B S，HAWKINS N，SCOTT D A. Network meta- of inconsistency in network meta-analysis[J]. Res Synth
analysis on the log-hazard scale，combining count and Methods，2016，7（1）：80-93.
hazard ratio statistics accounting for multi-arm trials：a [25] WINGERCHUK D M，ZHANG I，KIELHORN A，et al.
tutorial[J]. BMC Med Res Methodol，2010，10：54. Network meta-analysis of food and drug administration-
[14] SALANTI G，ADES A E，IOANNIDIS J P A. Graphical approved treatment options for adults with aquaporin-4
methods and numerical summaries for presenting results immunoglobulin G-positive neuromyelitis optica spec‐
from multiple-treatment meta-analysis：an overview and trum disorder[J]. Neurol Ther，2022，11（1）：123-135.
tutorial[J]. J Clin Epidemiol，2011，64（2）：163-171. （收稿日期：2022-08-01 修回日期：2023-01-10）
[15] NIKOO Z，BADIHIAN S，SHAYGANNEJAD V，et al. （编辑：刘明伟）

· 612 · China Pharmacy 2023 Vol. 34 No. 5 中国药房 2023年第34卷第5期